

9th Spring Meeting



March 4–6, 2019 • Norfolk, Virginia USA

Viral Vectors & Extracellular Vesicles

Cellular Therapies

Baculovirus Expression Technology

Viral Vaccines

Viral Vectors & Extracellular Vesicles

Chaired By:

Otto-Wilhelm Merten, PhD

Miltenyi Biotec Inc.

Mercedes Segura, PhD

bluebird bio Inc.

Aaron Noyes, EngD

Codiak BioSciences

Cellular Therapies

Chaired By:

Martin A. Giedlin, PhD

Poseida Therapeutics, Inc.

Lisa Stehno-Bittel, PhD

Likarda, LLC

Baculovirus Expression Technology

Chaired By:

Dominic Esposito, PhD

Frederick National Laboratory for Cancer Research

Antônio M. Roldão, PhD

Instituto de Biologia Experimental e Tecnológica (iBET)

Viral Vaccines

Chaired By:

Bernd Eichenmueller, PhD

Boehringer Ingelheim Vetmedica, Inc.

Philippe-Alexandre Gilbert, PhD

Sanofi Pasteur

Diane Wyatt

Wyatt CytoConsulting

SUNDAY • MARCH 3, 2019

4:00 pm – 7:00 pm

Welcome Reception and Registration in the Granby Ballroom Foyer, Third Floor

MONDAY • MARCH 4, 2019

7:00 am – 8:00 am

Registration and Breakfast in the Granby Ballroom Foyer, Third Floor

8:00 am – 8:30 am

Meeting Overview in Momentum, Third Floor

8:30 am – 9:15 am

9:15 am – 10:00 am

10:00 am – 10:30 am

	Viral Vectors & Extracellular Vesicles Momentum, Third Floor	Cellular Therapies Fusion, Third Floor	Baculovirus Expression Technology Energy, Third Floor	Viral Vaccines Paul D. Fraim Center for Excellence, Fourth Floor
8:30 am – 9:15 am	Darren W. Begley Ultragenyx Pharmaceutical	<i>3D In Vitro Screening for Cancer Immunotherapies</i> Lindsey Ott, PhD Likarda, LLC	<i>Baculoviruses as Insecticides</i> David A. Theilmann, PhD Agriculture and Agri-Food Canada	<i>High-Density Vero Cell Perfusion Culture in Single-Use Vessels</i> Michelet Dorceus Eppendorf North America
9:15 am – 10:00 am	<i>Producer Cell Line for Gene Therapy Development</i> Lois Horton Sanofi Genzyme	Sadik Kassim, PhD Mustang Bio, Inc.	<i>Baculovirus Biopesticides: Progress Towards Reaching Commercially Viable Yields of Bioreactor-Produced Occlusion Bodies by Exploring Gene Knock-Ins and CRISPR/Cas9 Knock-Outs of Production Cell Lines</i> Henry de Malmanche University of Queensland	<i>High Yield Viral Vaccine Production: Process Options and Monitoring</i> Udo Reichl Max-Planck-Institute for Dynamics of Complex Technical Systems

Morning Break in the Exhibit Area

ISBioTech 9th Spring Meeting (continued): MONDAY • MARCH 4, 2019

	Viral Vectors & Extracellular Vesicles <i>Momentum, Third Floor</i>	Cellular Therapies <i>Fusion, Third Floor</i>	Baculovirus Expression Technology <i>Energy, Third Floor</i>	Viral Vaccines <i>Paul D. Fraim Center for Excellence, Fourth Floor</i>
10:30 am – 11:00 am	Technology Workshop <i>Viral Vector Platform Vero Cell Lines for Production of Viral Vaccines and Viral Therapeutics</i> FUJIFILM Diosynth Biotechnologies Texas, LLC	Technology Workshop INCELL Corporation LLC	Technology Workshop Thermo Fisher Scientific	Technology Workshop <i>Engineering Better Viral Vectors Using Machine Learning and Synthetic Biology</i> ATUM
11:00 am – 11:30 am	Technology Workshop BIA Separations	Technology Workshop Pending	Technology Workshop Pending	Technology Workshop Novasep
11:30 am – 12:00 noon	Technology Workshop Vironova AB	Technology Workshop Pending	Technology Workshop Pending	Technology Workshop Pending
12:00 noon – 1:30 pm	Lunch in the Exhibit Area (Poster Session from 1:00 – 1:30 pm)			
1:30 pm – 2:15 pm	<i>Chemically Induced Extracellular Vesicles for Versatile Therapies via Facile and Scalable Production and Purification</i> Young Jik Kwon, PhD University of California, Irvine (UCI)	Vaughn Tunstall Genentech, a Member of the Roche Group	Highly Efficient Production of VLP-Based Vaccines by a Bioreactor-Free Novel BEVS Technology Romy M. Dalton, PhD Algenex, Inc.	<i>Highly Intensified, Low-Cost Vaccine Manufacturing Platform</i> Alfred Luitjens Batavia Biosciences
2:15 pm – 3:00 pm	<i>In Vitro Approaches to Demonstrating Potency of Gene Therapy Products</i> Anthony Leyme, PhD Biogen	<i>iPSC Technology: New Avenues for Blood Farming and Cell-Based Therapies</i> Mania Ackermann Hannover Medical School	Gale E. Smith, PhD Novavax, Inc.	<i>Turkey Herpesvirus as a Vector for Poultry Vaccines</i> Leticia Frizzo da Silva, DVM, PhD Ceva Animal Health, LLC
3:00 pm – 3:30 pm	Afternoon Break in the Exhibit Area			
3:30 pm – 4:15 pm	AAV and Baculovirus Vectors for the Treatment of Hyperammonemia Caused by Liver Failure Laura A. Palomares, ScD Universidad Nacional Autónoma de México (UNAM)	<i>Automation in Cell Therapy — What Problem(s) are We Trying to Solve?</i> Brian Hampson Hitachi Chemical Advanced Therapeutics Solutions, LLC	<i>Updated Evaluation of the Sf9 Cell Line</i> Arifa S. Khan, PhD FDA CBER	<i>Baculovirus Platform for Rapid Manufacturing of Seasonal Flu Vaccine at Large-Scale</i> Jamal Meghrous, PhD Protein Sciences Corporation, A Sanofi Company
4:15 pm – 5:00 pm	<i>Harness the Power of Exosomes: The Next Revolutionary “Small” Thing in Diagnostics and Regenerative Medicine</i> Behzad Mahdavi, PhD Lonza Inc.	<i>Manufacturing Solutions Driving Rapid Clinical Translation of hMSCs</i> Priya R. Baraniak, PhD RoosterBio Inc.	Production of Vaccine Antigens Using Drosophila S2 Insect Cells Wian A. de Jongh, PhD Expres2ion Biotechnologies	Speaker Pending
5:00 pm – 7:00 pm	Reception in the Exhibit Area			

TUESDAY • MARCH 5, 2019

	Breakfast in the Exhibit Area			
7:30 am – 8:30 am	Breakfast in the Exhibit Area			
8:30 am – 9:15 am	<i>Regulatory Updates for Virus-Based Human Gene Therapy Products</i> Anna Kwilas, PhD FDA CBER	<i>Keeping Pace with Product Development: Synergies Between Quality, Nonclinical, and Clinical Programs</i> Debra A. Webster, PhD Cardinal Health	<i>Optimizing the Baculovirus Expression System for Coxsackievirus VLP-Vaccine Production</i> Olli H. Laitinen, PhD University of Tampere	<i>Development of Suspension-Adapted Vero Cell Culture Technology for Viral Vaccine Production</i> Chun Fang Shen, PhD National Research Council Canada (NRC)
9:15 am – 10:00 am	<i>Therapeutic Potency of Stromal Cell Derived Extracellular Vesicles</i> Eva Rohde Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU)	<i>Cellular Cryoinjury and Potency – the Mesenchymal Stromal Cell Paradigm</i> Jacques Galipeau, MD University of Wisconsin-Madison	<i>Suitability and Perspectives of Different Insect Cell Factories for the Production of Antimicrobial Peptides</i> Jan Zitzmann Technische Hochschule Mittelhessen, Fachbereich LSE	<i>Multivariate Data Analysis for Reduction of Variation in a Viral Vaccine Production Process</i> Kevin Kent, PhD Boehringer Ingelheim Vetmedica, Inc.
10:00 am – 10:30 am	Morning Break in the Exhibit Area			

ISBioTech 9th Spring Meeting (continued): TUESDAY • MARCH 5, 2019

	Viral Vectors & Extracellular Vesicles <i>Momentum, Third Floor</i>	Cellular Therapies <i>Fusion, Third Floor</i>	Baculovirus Expression Technology <i>Energy, Third Floor</i>	Viral Vaccines <i>Paul D. Fraim Center for Excellence, Fourth Floor</i>
10:30 am – 11:15 am	Current State of Exosome-Based Diagnostics Johan Skog Exosome Diagnostics, Inc.	<i>Mitigating Supply Chain Challenges in Cell Therapies, and the Importance of Quality Apheresis — A Critical Starting Material</i> Mark Flower Be The Match BioTherapies, National Marrow Donor Program (NMDP)	<i>MultiBac: From Multi-protein Complex Structures to Synthetic Viral Nanosystems (SVNs)</i> Imre Berger, PhD University of Bristol	<i>Raw Materials Management: A Cornerstone for Risk Mitigation in Virus Safety Assurance of Biopharmaceuticals</i> Hazel Aranha, PhD Sartorius Stedim North America Inc.
11:15 am – 12:00 noon	<i>Triggering High-Yield Extracellular Vesicle Production for Regenerative Medicine</i> Amanda K.A. Silva Université Paris Diderot	<i>Improving the Preservation of PBMC and Purified T-cells</i> Chia-Hsing Pi University of Minnesota	The Over-Expression of Membrane Proteins for Structural Biology Using Baculovirus Andrew Quigley Diamond Light Source Ltd	<i>Historical Perspectives on the Use of Diverse Cell Substrates for Viral Vaccine Manufacturing</i> Robin Levis, PhD FDA CBER
12:00 noon – 1:30 pm	Lentivirus Reference Standard Working Group Meeting in Energy, Third Floor			
1:30 pm – 6:00 pm	Free Afternoon with Recommended Group Activities: River Cruise on the Victory Rover • Admission to Nauticus and the Battleship Wisconsin • Guided Historical Walking Tour • Glass Blowing Workshop at the Chrysler Glass Studio			
6:00 pm – 9:00 pm	Mardi Gras Banquet at the Granby Theater			

WEDNESDAY • MARCH 6, 2019

Breakfast in the Exhibit Area				
7:30 am – 8:30 am				
8:30 am – 9:15 am	<i>Bioprocessing of Cells and Exosomes for Regenerative Medicine</i> Ivan Wall, PhD Aston University	<i>Discussion on the Use of Non-Viral Cell Gene Modification for the Generation of CAR T-cells</i> Martin A. Giedlin, PhD Poseida Therapeutics, Inc.	<i>Walking with Insects: How Viruses Manipulate Insect Behaviour</i> Monique M. van Oers, PhD Wageningen University	Aaron C. Mack Biogen
9:15 am – 10:00 am	<i>Emerging Methods for Exosome Purification and Process Monitoring</i> Peter Gagnon BIA Separations	<i>T-cell Therapies: Building the Next Operating System</i> Genk Sumen, PhD Thermo Fisher Scientific	<i>The Influenza Virus Neuraminidase as a Vaccine Target</i> Florian Krammer, PhD Icahn School of Medicine at Mount Sinai	<i>Optimizing Cell Culture Medium for Cell Growth and Virus Productivity</i> Sandra K. McNorton MilliporeSigma
10:00 am – 10:30 am	Morning Break in the Exhibit Area			
10:30 am – 11:15 am	<i>Strategies and Advances in AAV Vector Characterization: Product-Related Impurities</i> Christine Le Bec, PhD Généthon	<i>Nucleofection: Bench to Clinic to Commercial</i> Gregory Alberts, PhD Lonza Walkersville, Inc.	Inês A. Isidro, PhD Instituto de Biologia Experimental e Tecnológica (iBET)	<i>Process Development and Analytical Characterization of the Adenovirus and Plasmid Components for the Vaccine-Based Immunotherapy Regimen</i> Lawrence C. Thompson, PhD Pfizer, Inc.
11:15 am – 12:00 noon	Potency Assays for Lentiviral Vectors Gillian Payne, PhD bluebird bio Inc.	<i>Regulatory and Development Strategies for Cell Therapies</i> Michael Day, PhD Voisin Consulting Life Sciences	<i>An Update on Glycoengineering and Adventitious Viruses in the Baculovirus-Insect Cell System</i> Donald L. Jarvis, PhD University of Wyoming	<i>Oncolytic Measles Virus Manufacturing: Linking Upstream and Downstream Strategies</i> Peter Czernak Technische Hochschule Mittelhessen, Fachbereich LSE
12:00 noon – 1:30 pm	Lunch in the Exhibit Area (Poster Session from 1:00 – 1:30 pm)			
1:30 pm – 2:15 pm	<i>Development of the 1st World Health Organisation International Standard for Gene Therapy Products</i> Yuan Zhao, PhD National Institute for Biological Standards & Control (NIBSC)	<i>Comparing Characterization Assays Across Different Cell Therapies</i> Francis Karanu, PhD Likarda, LLC	<i>Development of Multi-Subtype VLPs (msVLPs) as Broadly Protective Influenza Vaccines</i> Peter Pushko, PhD Medigen, Inc.	Marylou G. Gibson, PhD Virapur, LLC
2:15 pm – 3:00 pm	<i>Optimization of the Harvest and Clarification Steps for Purification and cGMP Manufacture of Sf9/Baculovirus-Derived rAAV Vectors</i> Daniel S. Hurwit Voyager Therapeutics	<i>Validating GMP-Compliant In Vitro Relative Potency Assays for Cell and Gene Therapy Products</i> Karen Doucette ACF Bioservices	Speaker Pending	Speaker Pending
3:00 pm – 3:30 pm	Afternoon Break in the Exhibit Area			
3:30 pm – 5:00 pm	Meeting Review and Discussion in the Paul D. Fraim Center for Excellence, Fourth Floor			
5:00 pm	Meeting Adjourns			

Due to circumstances beyond the control of meeting organizers, this program is subject to change without notice. REV 1/17/19